Who
Anne Prener
Director
Company insider
Files Form 4 as: Director, Keros Therapeutics; Director, Damora Therapeutics; Director, Rubius Therapeutics; Director, Kaleido Biosciences.
In numbers
- Trades disclosed
- 17
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 31 Dec 2019
- Last trade
- 1 Jul 2026
- Last filed
- 6 Jul 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jul 2026filed 6 Jul 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Code A | —13,786 at $0.00 | filing |
| 1 Jul 2026filed 6 Jul 2026 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,870 at $0.00 | filing |
| 1 Jul 2026filed 6 Jul 2026 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,870 at $0.00 | filing |
| 1 Jul 2026filed 6 Jul 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Code A | —13,786 at $0.00 | filing |
| 18 Jun 2025filed 20 Jun 2025 | DMRA Damora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —720 at $0.00 | filing |
| 20 Jun 2024filed 21 Jun 2024 | DMRA Damora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 14 Jun 2023filed 15 Jun 2023 | DMRA Damora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 14 Jun 2022filed 15 Jun 2022 | DMRA Damora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 12 May 2022filed 13 May 2022 | Rubius Therapeuticsoption or derivative | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 30 Jun 2021filed 1 Jul 2021 | Kaleido Biosciencesoption or derivative | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 26 May 2021filed 28 May 2021 | DMRA Damora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 12 May 2021filed 13 May 2021 | Rubius Therapeuticsoption or derivative | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 8 Jan 2021filed 8 Jan 2021 | DMRA Damora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 8 Jan 2021filed 8 Jan 2021 | DMRA Damora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
| 30 Jun 2020filed 1 Jul 2020 | Kaleido Biosciencesoption or derivative | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 1 Apr 2020filed 3 Apr 2020 | Kaleido Biosciencesoption or derivative | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 31 Dec 2019filed 3 Jan 2020 | Rubius Therapeuticsoption or derivative | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.